Lipocine Announces First Patient Dosed In Phase 1 Study In Pregnant Women Of LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth
September 08, 2014 at 16:00 PM EDT
Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced the first patient was dosed in a Phase 1 study in ...